Is Indivior Pharmaceuticals, Inc. (INDV) A Good Stock To Buy Now?

2 hours ago 1

Ricardo Pillai

Sat, June 13, 2026 astatine 8:54 AM CDT 3 min read

Is INDV a bully banal to buy? We came crossed a bullish thesis on Indivior Pharmaceuticals, Inc. connected The Mispricing Desk’s Substack. In this article, we volition summarize the bulls’ thesis connected INDV. Indivior Pharmaceuticals, Inc.'s stock was trading astatine $37.39 arsenic of June 8th. INDV’s trailing and guardant P/E were 19.30 and 12.27 respectively according to Yahoo Finance.

Galapagos NV (GLPG) Signs Agreement with Gilead connected Ouro Medicines Assets

Indivior (INDV) is simply a specialty pharmaceutical institution anchored by its SUBLOCADE franchise, which continues to thrust accelerating fundamentals and currency generation. On April 30, 2026, Indivior raised full-year guidance to $1.215–$1.285 cardinal successful nett gross and $620–$660 cardinal successful adjusted EBITDA aft reporting Q1 gross of $317 million, up 19% YoY, and adjusted EBITDA of $164 million, up 112%. SUBLOCADE remains the halfway maturation motor with $232 cardinal successful revenue, up 32%, supported by expanding adoption and implicit 500,000 cumulative patients treated.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

Despite discontinuing 2 pipeline programs pursuing mixed objective outcomes, the marketplace continues to anchor connected pipeline disappointment alternatively than improving profitability, stronger execution, and superior instrumentality acceleration. Within days of the guidance raise, Indivior announced a $175 cardinal accelerated stock repurchase scheduled for completion by end-June 2026, pursuing $125 cardinal of buybacks successful Q1, implying implicit 6% stock number simplification and reinforcing a wide displacement toward shareholder worth creation.

The equity inactive trades astatine astir 8.3x midpoint 2026 EBITDA, portion abbreviated involvement supra 11% of interval reflects lingering skepticism astir sustainability. However, the setup progressively reflects a rerating accidental arsenic EBITDA scales, leverage remains contained, and buybacks materially heighten per-share economics. Management’s pivot distant from low-return pipeline concern toward disciplined superior allocation strengthens visibility into net durability and escaped currency travel conversion.

With nett indebtedness manageable and SUBLOCADE continuing to expand, the catalyst way centers connected ASR colony mechanics and ongoing net validation. If sentiment normalizes, rerating toward 9–10x EBITDA implies meaningful upside, portion downside appears supported adjacent $35 fixed de-risked guidance and progressive superior returns. Indivior progressively resembles a self-funding compounder mispriced owed to bequest pipeline concerns alternatively than existent operating momentum and accelerating shareholder yield.

Read Entire Article